Maxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.Analyst Jason Kolbert highlighted:Gilead reported quarterly results with total top-line ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Downgrades

Gilead Sciences (GILD) PT Lowered to $118 at UBSApril 29, 2016 8:27 AM Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 TreatmentApril 29, 2016 8:11 AM Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO CapitalApril 29, 2016 7:40 AM Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C SalesApril 29, 2016 7:30 AM Gilead Sciences (GILD) PT Trimmed to $123 at Leerink PartnersApril 29, 2016 6:50 AM Gilead Sciences (GILD) Raises Quarterly Dividend 9.3% to $0.47; 1.9% YieldApril 28, 2016 4:07 PM Gilead Sciences Announces Second Quarter 2016 DividendApril 28, 2016 4:06 PM Gilead Sciences (GILD) Misses Q1 EPS by 10cApril 28, 2016 4:05 PM Gilead Sciences Announces First Quarter 2016 Financial ResultsApril 28, 2016 4:02 PM